NCT05758129 is a clinical trial in Exposure to Polluted Air, sponsored by Affiliated Hospital of Jiangnan University.

Who is sponsoring NCT05758129?

NCT05758129 is sponsored by Affiliated Hospital of Jiangnan University.

What condition does NCT05758129 study?

NCT05758129 studies Exposure to Polluted Air.

Is NCT05758129 still recruiting?

NCT05758129 is currently status unknown. Last updated 7 March 2023.

Last reviewed 2023-03-07 · How we verify

NCT05758129

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Association Between PM2.5 Exposure and Ferroptosis in Seizures Patients

Status unknown Last updated 7 March 2023

What this trial tests

trial in Exposure to Polluted Air in 60 participants. Status unknown.

Timeline

1 December 2022

Primary endpoint
10 March 2023

25 March 2023

Quick facts

Lead sponsor	Affiliated Hospital of Jiangnan University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	60
Start date	1 December 2022
Primary completion	10 March 2023
Estimated completion	25 March 2023
Sites	1 location across China

Conditions studied

Exposure to Polluted Air — all drugs for Exposure to Polluted Air →

Sponsor

Affiliated Hospital of Jiangnan University

Who can join

Adults 6 to 18, any sex, with Exposure to Polluted Air. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This cohort study aims to discover the possible effects of PM2.5 exposures on the Nrf2- dependent ferroptosis pathway in seizure patients. This observational cohort's main question is whether PM2.5 exposures will affect the Nrf2- dependent ferroptosis pathway in seizure patients. Participants will be divided into two groups: the control group and the air pollution to detect the biomarkers of the Nrf2- dependent ferroptosis pathway in seizure patients

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

In defence of ferroptosis.
Alves F, Lane D, Nguyen TPM, Bush AI, et al · · 2025 · cited 75× · PMID 39746918 · DOI 10.1038/s41392-024-02088-5

Verify or expand the search:

Other Affiliated Hospital of Jiangnan University trials

Trials by the same sponsor.

NCT07023861 — The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies · EARLY_PHASE1 · enrolling by invitation
NCT07023848 — PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors · EARLY_PHASE1 · enrolling by invitation
NCT07162779 — Evaluation of [68Ga]DOTA-IR-780-C-4 in PET Imaging Studies for PSMA-Positive Prostate Cancer Patients · NA · enrolling by invitation
NCT06448975 — An Exploratory Study of Deep Cervical Lymphovenous Bypass (LVB) in Alzheimer's Disease · NA · recruiting
NCT06723665 — The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05758129 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital of Jiangnan University
Last refreshed: 7 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05758129.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing